ESTIMATION OF THE ABSOLUTE BIOAVAILABILITY OF FLECAINIDE USING STABLE-ISOTOPE TECHNIQUE

被引:1
作者
HAGE, K
BUHL, K
FISCHER, C
KNEBEL, NG
机构
[1] DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL,D-70376 STUTTGART,GERMANY
[2] ROBERT BOSCH KRANKENHAUS,ZIM,KARDIOL ABT,D-70376 STUTTGART,GERMANY
关键词
FLECAINIDE; BIOAVAILABILITY; STABLE ISOTOPE; ABSORPTION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Data on the absolute bioavailability of flecainide are controversial. We have investigated whether differences in metabolic clearances and/or the absorption profile might be responsible for the variability in its absolute bioavailability. Six subjects with a wide range of flecainide metabolic clearances (85-407 ml . min(-1)) simultaneously received the drug by the IV and oral routes; the oral dose was labelled with deuterium. Besides estimation of absolute bioavailability, this design permitted assessment of metabolic clearance after IV and oral administration, and absorption could be assessed from the urinary excretion of labelled and unlabelled drug and metabolites. The absolute bioavailability of flecainide ranged from 79.9 to 101.1 % (mean 93.6 %). The absorption was 86.1 to 101.3 % (mean 93.2 %). The data indicate that the variable bioavailability of flecainide is due both to metabolism and absorption. The study highlights the potential of stable isotope technique in the investigation of such issues.
引用
收藏
页码:51 / 55
页数:5
相关论文
共 16 条
[1]   STEREOCHEMISTRY, A BASIS FOR SOPHISTICATED NONSENSE IN PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY [J].
ARIENS, EJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (06) :663-668
[2]   IS THERE A GENETIC-FACTOR IN FLECAINIDE TOXICITY [J].
BECKMANN, J ;
HERTRAMPF, R ;
GUNDERTREMY, U ;
MIKUS, G ;
GROSS, AS ;
EICHELBAUM, M .
BRITISH MEDICAL JOURNAL, 1988, 297 (6659) :1316-1316
[3]  
CONARD GJ, 1979, CLIN PHARMACOL THER, V25, P218
[4]   METABOLISM OF FLECAINIDE [J].
CONARD, GJ ;
OBER, RE .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (05) :B41-B51
[5]   DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
STEINCKE, B ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187
[6]   SUPERIORITY OF STABLE ISOTOPE TECHNIQUES IN THE ASSESSMENT OF THE BIOAVAILABILITY OF DRUGS UNDERGOING EXTENSIVE 1ST PASS ELIMINATION - STUDIES OF THE RELATIVE BIOAVAILABILITY OF VERAPAMIL TABLETS [J].
EICHELBAUM, M ;
DENGLER, HJ ;
SOMOGYI, A ;
VONUNRUH, GE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 19 (02) :127-131
[7]   SIMULTANEOUS ASSESSMENT OF THE INTRAVENOUS AND ORAL DISPOSITION OF THE ENANTIOMERS OF RACEMIC NIMODIPINE BY CHIRAL STATIONARY-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND GAS-CHROMATOGRAPHY MASS-SPECTROSCOPY COMBINED WITH A STABLE ISOTOPE TECHNIQUE [J].
FISCHER, C ;
SCHONBERGER, F ;
MUCK, W ;
HEUCK, K ;
EICHELBAUM, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (03) :244-250
[8]   DETERMINATION OF THE ENANTIOMERS OF FLECAINIDE AND 2 MAJOR METABOLITES IN MAN BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY USING NEGATIVE-ION CHEMICAL IONIZATION AND STABLE ISOTOPE LABELED INTERNAL STANDARDS [J].
FISCHER, C ;
SCHONBERGER, F ;
MEESE, CO ;
EICHELBAUM, M .
BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1990, 19 (04) :256-266
[9]   STEREOSELECTIVE DISPOSITION OF FLECAINIDE IN RELATION TO THE SPARTEINE DEBRISOQUINE METABOLIZER PHENOTYPE [J].
GROSS, AS ;
MIKUS, G ;
FISCHER, C ;
HERTRAMPF, R ;
GUNDERTREMY, U ;
EICHELBAUM, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (05) :555-566
[10]  
GROSS AS, 1991, EUR J CLIN PHARMACOL, V40, P155